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ABSTRACT
The progression and clonal development of tumors
often involve amplifications and deletions of genomic DNA. Estimation of allele-specific copy number, which quantifies the number of copies of each
allele at each variant loci rather than the total number of chromosome copies, is an important step in
the characterization of tumor genomes and the inference of their clonal history. We describe a new
method, falcon, for finding somatic allele-specific
copy number changes by next generation sequencing of tumors with matched normals. falcon is based
on a change-point model on a bivariate mixed Binomial process, which explicitly models the copy numbers of the two chromosome haplotypes and corrects
for local allele-specific coverage biases. By using
the Binomial distribution rather than a normal approximation, falcon more effectively pools evidence
from sites with low coverage. A modified Bayesian
information criterion is used to guide model selection for determining the number of copy number
events. Falcon is evaluated on in silico spike-in data
and applied to the analysis of a pre-malignant colon
tumor sample and late-stage colorectal adenocarcinoma from the same individual. The allele-specific
copy number estimates obtained by falcon allows
us to draw detailed conclusions regarding the clonal
history of the individual’s colon cancer.
INTRODUCTION
Each person inherits two copies of the genome. Tumor
cells often undergo somatic structural mutations that delete
or amplify certain chromosomal segments in one or both
copies. Detecting and characterizing these mutations, called
somatic copy number aberrations, are an important step in
the study of the tumor. As an integral component in the tumor’s genetic profile, knowledge of somatic copy number
* To

aberrations can lead to insights into the tumor’s genetic history and may allow for more accurate prognosis and more
appropriate treatment for the patient.
Copy number aberrations were traditionally studied by
spectral karyotyping and more recently by comparative
genome hybridization (CGH) and high-density single nucleotide polymorphism genotyping arrays. CGH allows the
relative quantification, with respect to a control sample, of
the total copy number of the two inherited homologous
chromosome copies (see (1) and (2) for a review). By measuring the quantity of both alleles at heterozygous loci,
genotyping arrays allow the estimation of the copy numbers
of each allele, sometimes called allele-specific copy number
(ASCN) (3–11).
With the advance of sequencing technology, wholegenome and whole-exome sequencing can now be used to
quantify DNA copy number and detect structural variation. Many computational and statistical methods have
been developed for the analysis of DNA sequencing data
(see (12) for a review). In particular, tools have been developed for detecting structural variants based on read coverage. Sequencing produces reads containing both alleles at
heterozygous variant loci, and thus, like genotyping arrays,
allows the disambiguation of ASCNs. Compared to genotyping arrays, next-generation sequencing can provide finer
resolution in estimating ASCNs because each person has
his/her own unique heterozygous variant loci that are not
included in regular genotyping arrays.
Compared to total copy number analysis, ASCN analysis gives a much more complete picture of the mutation
profile of tumors. Some types of somatic mutations, such as
gene conversion and mitotic recombination, replace a region on one chromosome by the same region duplicated
from the other homologous copy. These loss of heterozygosity (LOH) events do not change the total DNA copy
number, but they do change the copy number of each chromosome haplotype in the region involved. Also, when total DNA copy number changes, it is important to know
whether one or both of the inherited alleles are involved.
For alleles that represent known variants of genes, it is often of biological interest to know which variant has under-
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gone copy number change. Finally, precise ASCN estimates
allow for accurate estimates of tumor purity and malignant
cell ploidy. For example, algorithms such as ABSOLUTE
(13) utilize ASCNs as inputs.
Patchwork (14) made an advance in estimating ASCN on
next generation sequencing data. Patchwork first segments
the genome by total coverage, and then, within each segment, estimates the ASCN. Since the segmentation is by
total coverage, Patchwork cannot find somatic mutations,
such as gene conversion, which change the ASCN but not
the total copy number. Also, since allelic imbalance is not
used by Patchwork in the segmentation step, its segmentation accuracy is comparable to methods based only on total
coverage.
In this paper, we propose a new method, falcon, for
finding somatic allele-specific copy number changes by
next-generation sequencing of tumors. It uses allele-specific
coverage to segment the genome and thus can detect somatic mutations that change the ASCN but not the total
copy number. We show via spike-in studies that by using
more information from the data, falcon is more sensitive
than methods based on total coverage, even for detecting
events with total copy number change. By applying FALCON to a trio of normal, pre-malignant tumor and late-stage
colorectal adenocarcinoma samples from the same individual, we show that accurately estimated ASCNs allow one to
draw conclusions about clonal history that would have been
impossible using total copy number alone.
Estimating ASCNs from sequencing data is difficult due
to the large amount of noise and artifacts that are intrinsic
to the experiment. It is commonly known that sequencing
coverage is dependent on characteristics of the local DNA
sequence and fluctuates even when there is no change in total copy number. The top panel of Figure 1 plots the total
coverage at heterozygous single nucleotide variant (SNV)
loci on Chromosome 19 from the normal sample from the
trio described under Materials and Methods. The coverage
varies over a large range, from as small as 3 to as large as 79,
even in a normal sample. As for total copy number, such local biases complicate the estimation of ASCN, but whereas
total copy number can be modeled as piecewise constant,
ASCN depends on the latent phase and thus the noise can
not be reduced by averaging adjacent values. There can also
be substantial allelic biases at heterozygous loci due to the
preference for one of the alleles in mapping. As shown in
the bottom panel of Figure 1, which plots the log allelic ratio (ratio of coverages of the B- and A- alleles), the observed
allelic coverage ratio varies from 0.1 to 5.8 on the linear scale
in this normal sample. Some of this variation is due to true
allelic imbalance, but most are due to noise. falcon is based
on a new change-point model on a bivariate mixed Binomial
process, which explicitly models the copy numbers of the
two chromosome haplotypes in the tumor sample and empirically corrects for allele-specific coverage biases by conditioning on a matched normal sample. The matched normal
sample must be sequenced and mapped using the same protocol as the tumor sample.
falcon is available as an R package, which can be viewed
at http://cran.us.r-project.org/web/packages/falcon/ and installed within R. falcon includes functions for genome segmentation, ASCN estimation and data visualization. The

Downloaded from https://academic.oup.com/nar/article-abstract/43/4/e23/2410993
by guest
on 12 July 2018

PAGE 2 OF 10

Figure 1. Total coverage (top plot) and log allelic ratio (bottom plot) over
all heterozygous loci on Chromosome 19 from the normal sample sequenced to 45×.

program also gives an estimate of the latent phase of the
heterozygous variant loci.
MATERIALS AND METHODS
Materials
We will analyze sequencing data on three different tissues
of a patient with a malignant colon adenocarcinoma. The
three tissues are normal sigmoid colon tissue, a sigmoid
colon tumor that was judged at biopsy to be pre-malignant,
and a stage 3B colon adenocarcinoma (malignant). The
first two samples were collected at the same time, and the
third sample was collected 15 months later. All three samples from this individual were sequenced to an average of
45× coverage on the Illumina HiSeq platform with 100 base
paired-end reads. Heterozygous single nucleotide variant
sites were called in the normal sample using GATK.
Bivariate mixed binomial change-point model for ASCNs in
tumor and matched normal
We assume that a set of T inherited heterozygous loci have
been identified on the matched normal sample. Our model
compares the allele-specific coverage at these inherited heterozygous sites in the tumor to those in the matched normal
to find somatic allele-specific changes.
Let the two alleles at each bi-allelic loci be A and B. At
heterozygous loci t, let XtA and XtB be the allele-specific coverages, defined as the number of reads containing each al-
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lele, in the tumor sample. Similarly, let YtA and YtB be the
allele-specific coverages at loci t in the matched normal.
Our goal is to estimate the ASCNs at each heterozygous
loci, relative to the matched normal. To motivate our model,
consider the example in Figure 2, taken from the data described in the previous section. The normal sample in this
example is the normal sigmoid colon tissue and the tumor
sample is the stage 3B malignant sample. The region shown
spans 100 heterozygous loci containing, at the center, the
first event (a deletion of size 57 kb) in group E in Table
2. To avoid an overcrowded plot, we only plot every third
loci in this region, and thus 34 loci are shown in the plot.
The top plot shows the observed coverages of alleles A and
B in the normal and the tumor. The bottom panel shows
the estimated copy numbers, relative to the normal, of the
two inherited haplotype chromosomes in solid and dashed
lines, as well as the estimated ASCNs from falcon for the
34 loci (empty triangles, for A and for B). The observed
ASCNs, shown as solid triangles in the bottom plot, can
be computed from the allele-specific coverages by Equation
(6) given below. Relative ASCN is 1 when there is no difference from normal. As seen from the bottom panel, one
of the chromosomes has a loss of ∼0.41-fold in the middle
region. An obvious but important fact, represented in the
bottom panel, is that an allele’s copy numbers is equal to
the haplotype-specific copy number of the chromosome on
which the allele resides. Haplotype-specific copy numbers
are piecewise constant, but unphased ASCNs are not.
The observed allele-specific coverages and allelic ratios
are influenced by many experimental biases and artifacts.
Since coverage is affected by local fragmentation, sequencing and mapping biases, without adjusting to the matched
normal, absolute coverage does not reflect true absolute
copy number. Also, the observed ratio of B-allele coverage
to total coverage often deviate from the expected value of
50%, even in the normal sample when there is no allelic
imbalance. Hence, one must take into account the biases
reflected in the normal sample when making inferences regarding allelic imbalance in the tumor.
To control for the biases in sequencing data, we model the
conditional distribution of the coverage of each allele in the
tumor given the total coverage of that allele across the tumor and normal samples. Let n tA = XtA + YtA, n tB = XtB +
YtB . Let Bin(n, p) denote a binomial distribution with n trials and success probability p. Assume that there are an unknown K + 1 segments of homogeneous underlying haplotype copy number, with change-points at τK = (τ1 , . . . , τK )
that are constrained to lie in the set
DK = {(t1 , . . . , tK ) : 0 < t1 < · · · < tK < T}.
To simplify future notation we augment τK with fixed endpoints τ 0 = 0 and τ K + 1 = T. Then, conditional on (n tA, n tB ),
we model the allele-specific coverages in the tumor as a twocomponent mixture of binomials,
(XtA, XtB )|(n tA, n tB ) ∼ 1/2(Bin(n tA, pka ), Bin(n tB , pkb ))
+1/2(Bin(n tA, pkb ), Bin(n tB , pka )),
for t = τk + 1, τk + 2, . . . , τk+1 , fork = 0, . . . , K. (1)
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In the Appendix we describe a procedure to estimate K, the
change-points τK and the success probabilities {( pka , pkb ) :
k = 0, . . . , K} from the data. The success probabilities can
then be converted to ASCNs, as we show below.
We first explain this model in more detail. Let the two
haplotype chromosomes be arbitrarily labeled a and b.
We observe allele-specific coverage, but without knowing
whether allele A is on haplotype a or b, we do not know
the haplotype-specific coverage. Let It be a latent indicator
variable that equals 1 if allele A is on chromosome a, and 0
otherwise. Consider the hypothetical situation where we observe It , then we would observe the haplotype-specific coverage, which we denote by Xta and Xtb for the tumor sample
and by Yta and Ytb for the matched normal. Xta , Xtb , Yta , Ytb
can be modeled by independent Poisson random variables
with location-specific means:
Xta ∼ Poisson(μa (t)),

Xtb ∼ Poisson(μb (t)),

Yta ∼ Poisson(λa (t)),

Ytb ∼ Poisson(λb (t)). (2)

By a simple relationship between the Binomial and Poisson
distributions, we have,
Xta |n at ∼ Bin(n at , pa (t)),

Xtb |n bt ∼ Bin(n bt , p b (t)),

where
n at = Xta + Yta ,
pa (t) =

n bt = Xtb + Ytb ,

μa (t)
,
μa (t) + λa (t)

p b (t) =

μb (t)
.(3)
μb (t) + λb (t)

The Poisson means in (2) depend on many factors: The total
number of reads sequenced (denoted by M and N, respectively, for normal and tumor), the true relative haplotypespecific copy numbers (which, by definition, is equal to 1
in the normal and denoted by Ca (t) and Cb (t), respectively,
for the a and b haplotype in the tumor), local biases due to
ease of fragmentation and mapability and allele-specific biases. If we make the simple assumption that these factors
are multiplicative, which is equivalent to assuming a conventional log-linear model for the read counts, then
t
λa (t) = Mh(t)b IAt (t)b1−I
B (t),

It
t
λb (t) = Mh(t)b1−I
A (t)b B (t),
t
μa (t) = NC a (t)h(t)b IAt (t)b1−I
B (t),

It
t
μb (t) = NC b (t)h(t)b1−I
A (t)b B (t),

where h(t) ∈ (0, ∞) is the site-specific bias in total coverage,
and bA (t), bB (t) ∈ (0, ∞) are the site-specific biases specific
to alleles A and B. The key insight is that these nuisance
bias terms cancel out in the success probabilities (3), which
evaluate to
pa (t) =

NC a (t)
,
NC a (t) + M

p b (t) =

NC b (t)
. (4)
NC b (t) + M

Since copy number change is abrupt, it is appropriate to assume that Ca (t) and Cb (t) are piecewise constant functions
of t, which is equivalent to a change-point model on the suc-
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Figure 2. Observed allele-specific coverage at 34 loci in an example region containing an estimated 0.41-fold deletion of one parental chromosome. Top
panel shows the allele-specific coverages in tumor (gray) and normal (white). Each grouped barplot corresponds to one loci location, with reads of the A
allele on the left and reads of the B allele on the right. Bottom panel shows the estimated parental copy numbers of the two inherited chromosomes (in
bold and dashed lines) for the tumor relative to matched normal. Empty triangles show the estimated ASCNs from falcon for the 34 loci in the region.
Solid triangles show the observed ASCNs computed by Equation (6).

cess rates {pa (t), pb (t)), t = 1, . . . , T}:


pa (t) = pka
if tk < t ≤ tk+1 , k = 1, . . . , K.
p b (t) = pkb

(5)

In practice, we do not observe It , but by Mendel’s law of
equal segregation, we know that P(It = 1) = 1/2. Thus, the
observed allelic coverages are mixtures with distribution (1).
With pa (t) and pb (t) estimated using the procedure given
in the Appendix, the haplotype-specific copy numbers can
be obtained by inverting (4). For visualization, falcon plots
observed allele-specific relative copy numbers, which can be
computed from the allele-specific coverages as follows: First
compute p̃ A(t) = XtA/n tA, p̃ B (t) = XtB /n tB . Then, the observed ASCNs in the tumor, relative to the normal, is defined as
C A(t) =

M
p̃ A(t)
× ,
1 − p̃ A(t)
N

C B (t) =

M
p̃ B (t)
× . (6)
1 − p̃ B (t)
N

In the example in Figure 2, CA (t) and CB (t) are shown
in solid triangles in the bottom panel. Due to noise and
sampling error, the observed ASCNs can vary substantially
from the true values, especially at sites with lower coverage.
In our discussion, we will call the estimated values of
Ca (t) and Cb (t) given by falcon the allelic ratios, since they
are the ratios of the haplotype copy numbers in the tumor
versus that in the normal. Since the labeling of a and b is
arbitrary, we will always assign Ca (t) to the smaller of the
two allelic ratios at each site. We call Ca (t) the minor allelic
ratio, and Cb (t) the major allelic ratio. An estimated allelic
ratio that is significantly less than one indicates a putative
haplotype loss, and one that is significantly greater than one
indicates a putative haplotype gain. In this way, all genomic
regions that have undergone copy number change can be
categorized into one of six possible types: Gain of one allele, with the other allele at normal level (gain/normal), gain
of both alleles (gain/gain), loss of one allele (normal/loss),
loss of both alleles (loss/loss), gain of one allele accompanied by balanced loss of the other allele (balanced gain/loss)
and gain of one allele accompanied by unbalanced loss of
the other allele (unbalanced gain/loss). Accurate event categorization and allelic ratio estimation make possible the
clonal history analysis in the next section.
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Figure 3. Major and minor allelic ratios for the pre-malignant and the
stage 3B tumor samples, plotted versus genome position. Losses are shown
in blue and gains are shown in red. Normal copy number are shown in
green.

RESULTS
Clonal analysis of a late-stage colorectal adenocarcinoma
Overview of analysis. We analyzed the three samples from
the patient with a malignant colon adenocarcinoma (see
Materials and Methods for more details of the data). The
allele-specific coverages at heterozygous single nucleotide
variant sites in the pre-malignant and malignant tumors
were analyzed using falcon with the normal sample as the
control, resulting in the segmentation of the genomes of
the pre-malignant and malignant samples into regions of
homogeneous ASCN. To focus our analysis on high confidence calls, we filtered for regions where the change in allelic ratios from 1 is larger than 0.2, which gave us a sizable
list containing both focal and broad copy number changes,
with a total of 46 events in the pre-malignant sample and
32 events in the stage 3B tumor. The estimated major and
minor allelic ratios are shown in the whole-genome plot of
Figure 3. Both the full set of unfiltered regions as well as the
reduced set of high confidence regions in the pre-malignant
and stage 3B adenocarcinoma samples are given in Supplementary Materials. From Figure 3, one easily recognizable
event is LOH of chromosome 3p, which has been commonly
observed in carcinoma of various tissues, including colorectal carcinoma. The LOH of 3p, as well as many other events,
are found in both the pre-malignant and the stage 3B tumor,
which is strong evidence that the pre-malignant tumor is a
genetic precursor to the advanced stage tumor extracted 2
years later.
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Validation of focal events. We used digital droplet polymerase chain reaction (ddPCR) to validate a selection of
calls made by falcon. We selected those calls that are more
challenging to make: Small, focal loss of only one chromosomal copy. We defined an event to be ‘focal’ if it is
smaller than 1 megabase. Due to the unreliable calling of
these events by standard software, these types of events are
often ignored in studies. In the stage 3B tumor, 9 focal single copy losses are called, ranging in size from 509 bases
to 770 kilobases. Of these events, four were also present in
the pre-malignant sample. We conducted ddPCR on these 9
regions for both the pre-malignant and advanced stage tumor sample. The details of ddPCR are in the Appendix. In
the Appendix, we also show detailed plots of these events
including the A allele frequency, relative coverage and the
observed and estimated ASCNs.
The events submitted to ddPCR validation are shown in
Table 1. Of the 9 single-copy focal losses called in the malignant sample, 7 were validated by ddPCR, and of the four
events that were also independently identified as single-copy
losses in the pre-malignant sample, three were validated by
ddPCR. The three disagreeing calls between ddPCR and
FALCON are highlighted in red in the table. Event 7 is a very
small region of 509 bases covered by only 10 loci, which
by visual inspection is likely to be a false-positive call by
falcon. Event 4, on chromosome 3, was called in both samples by falcon, but not called in either sample by ddPCR.
Despite this disagreement with ddPCR, we believe the call
made by falcon might be true due to the following reasons:
(i) This 278 kb region is called independently in both the
pre-malignant and late-stage tumor, with exact breakpoint
overlap. (ii) The region is supported by 154 loci, and is visually convincing in both samples. (iii) Apart from the allelespecific coverage used by falcon, the deletion of this region is also supported by 8 telescoping read pairs in the premalignant sample and 4 telescoping read pairs in the malignant sample. (iv) The allelic ratios of Event 4 agree well with
the allelic ratios for the other events called in both samples,
which would be expected if they were from the same clone.
(See in the Appendix the detailed plots of this event.) If we
assume that ddPCR is 100% correct, then 10 out of the 13
(77%) calls made by FALCON in Table 1 are true. If we assume that ddPCR made a false negative for Event 4, then
the accuracy of FALCON for such focal single-copy deletions
in these two samples is 12 out of 13 (92%).
Clonal history. The ASCN estimates given by FALCON allow us to make detailed inference on the clonal history of
the pre-malignant and stage 3B tumor samples. For each
mutation event, we define the event-specific purity (f) as the
proportion of cells within the sample that carry the mutation. Note that this definition is based on counting cells, not
chromosomes, and so, for example, a heterozygous loss that
is carried by every cell would have a event purity of 100%,
not 50%.
For the pre-malignant and malignant samples, we can directly compute an estimate of f for normal/loss and balanced gain/loss regions from the estimated major and minor allelic ratios given by FALCON (details in the Appendix).
Figure 4 plots the estimated event-specific purities in the
pre-malignant sample versus that in the advanced stage tu-
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Figure 4. Event-specific purities in the pre-malignant sample versus that in
the advanced stage tumor for normal/loss and balanced gain/loss events.
The events fall into four clusters, which we mark by A, C, D and E.

mor for normal/loss and balanced gain/loss events. The
events in the scatterplot cluster cleanly into four groups,
which we call A, C, D and E. Note that unlike conventional
statistical cluster analysis, we can be quite confident in assigning a group to only one event (e.g. A) if that event is supported by a large number of loci. In this case, the sole event
in group A is a large deletion of ∼15 megabases on chromosome 14. This event covers more than 10 000 heterozygous
SNVs in both the pre-malignant and malignant tumor samples, and thus the standard errors on its estimated purity in
the two samples are extremely small. Group D also contains
broad events, including the balanced gain/loss on 3p covering more than 37 000 SNVs. Hence, we are quite confident
that the event in group A forms its own distinct cluster separate from group D. The events in each group are listed in Table 2. All four groups contain high confidence calls that are
supported by at least a few hundred SNVs. Furthermore,
three focal events in group D and four focal events in group
E are validated by ddPCR (bold rows in Table 2). Thus, we
can be fairly certain of the existence of these four groups as
well as the accuracy of their purity estimates, which manifests in the tightness of the clusters.
Based on the tight clustering of event-specific purities in
Figure 4, we can infer the evolutionary history for this trio
of samples (see the Appendix). The two plausible histories
for this tumor are shown in the form of binary trees in Figure 5. Only two histories are plausible given the data. The
two plausible histories differ only in the placement of mutation group C, which impacts the estimate of the normal cell
proportion in the pre-malignancy sample. Since mutation
group C is not found in the advanced stage tumor, the position of group C in the tree does not impact the fundamental
biological conclusions that we were able to draw: (i) There is
one dominant clone in the advanced stage tumor, and this
dominant clone descends from precursor cells in the pre-
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Table 1. The estimated total copy numbers from FALCON and ddPCR (in parentheses) for the 9 focal events
Total copy number by falcon (ddPCR)
Event#

Chr

# SNVs

Start

# bases (kb)

Pre-malignant

Stage 3B tumor

1
2
3
4
5
6
7
8
9

1
1
3
3
4
4
6
7
12

330
328
470
154
50
10
70
140
210

70 460 759
169 823 686
187 689 874
192 000 794
113 949 726
189 296 696
107 093 876
66 968 908
2 978 048

576.9
770.5
449.3
278.6
57.0
0.5
101.7
115.3
213.5

1.32 (1.30)
1.34 (1.29)
1.32 (1.31)
1.35 (1.99)
2.00 (1.82)
2.00 (1.95)
2.00 (1.93)
2.00 (1.92)
2.00 (1.98)

1.50 (1.72)
1.56 (1.44)
1.52 (1.52)
1.56 (2.03)
1.59 (1.56)
1.31 (1.96)
1.56 (1.53)
1.59 (1.57)
1.59 (1.55)

Table 2. Events in each group defined in Figure 4. The last column gives the number of SNVs supporting each event. The bold events are validated by
ddPCR
Group
A
C
C
C
C
D
D
D
D
D
D
D
D
E
E
E
E
E
E
E

Chr
14
8
10
11
17
1
1
1
3
3
3
3
6
4
6
7
9
12
14
18

Start (bp)

Length (bp)

Type

65 203 499
13 108 550
99 499 503
196 912
55 044 007
70 460 759
145 736 308
169 823 686
61 466
187 689 874
192 000 794
193 174 341
156 915 215
113 949 726
107 093 876
66 968 908
133 572 684
2 978 048
92 074 218
48 554 285

14 874 210
9160
1 373 470
4488
960 025
576 917
1 645 136
770 484
48 941 046
449 276
278 599
4 102 786
8 849 153
56 958
101 700
115 254
2 136 903
213 515
10 949 862
29 176 315

Normal/Loss
Normal/Loss
Normal/Loss
Balanced Gain/Loss
Normal/Loss
Normal/Loss
Normal/Loss
Normal/Loss
Balanced Gain/Loss
Normal/Loss
Normal/Loss
Normal/Loss
Normal/Loss
Normal/Loss
Normal/Loss
Normal/Loss
Normal/Loss
Normal/Loss
Normal/Loss
Normal/Loss

malignant tumor. (ii) The progression from pre-malignant
lesion to malignancy involved at least three waves of mutations containing, in temporal order from earliest to latest,
mutation groups D, A and E.

Figure 5. Plausible clonal histories for the malignant colorectal adenocarcinoma. There are two histories that agree with the evidence from eventwise purities in Figure 4, expressed by binary trees with mutation groups
A, C, D, E on the edges indicating the events that distinguish that lineage. Each tree is observed at two time points, first at the collection of the
pre-malignant tumor, and then at the stage 3B malignant lesion 2 years
later. The estimated sizes of the clonal subpopulations are shown under
the boxes. The lengths of the branches are arbitrary, since without further
strong assumptions, we can not infer branch length from this data.
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Num. SNVs
10 674
44
800
4
730
330
776
328
37 440
470
154
3708
7600
50
70
140
1640
210
8026
21 828

Table 3. The smallest tumor purity under which the type of aberration can
be correctly detected by falcon, and under which the region of the change
is found by seqCBS, which considers only total copy number
Type of change

falcon

BS

Loss/Loss
Gain/Gain
Unbalanced
Gain/Loss
Balanced Gain/Loss
Normal/Loss
Gain/Normal

15
15
15

15
35
70

25
25
25

NA
60
75

The proportion of normal cells is estimated at 55% for
the advanced stage tumor sample in both plausible histories. For the pre-malignant sample, the two histories differ:
Under history 1, which assumes that those cells carrying
mutation group C also carry mutation group D, the normal
cell contamination fraction is estimated to be 43%, whereas
under history 2, which assumes that the cells carrying mutation group C do not carry D, the normal cell contamination
fraction is estimated to be less than 5%.
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Table 4. The smallest tumor purity under which the type of aberration can
be correctly detected by falcon, and under which the region of the change
is found by seqCBS (in parentheses), under different coverage (44×, 22×
and 11×)

Loss/Loss
Gain/Gain
Unbalanced
Gain/Loss
Balanced
Gain/Loss
Normal/Loss
Gain/Normal

44×

22×

11×

15 (15)
15 (35)
15 (70)

15 (10)
20 (35)
25 (75)

20 (15)
25 (35)
30 (85)

25 (––)

35 (––)

45 (––)

25 (60)
25 (75)

35 (60)
40 (75)

50 (70)
55 (85)

Figure 6. The spike-in data are created by adding the six types of aberrations to chromosome 7 of the real sequencing data from the normal sample.
Dashed lines in the figure show the true copy number in the spike-in set.
Estimated copy numbers by FALCON at 25% tumor purity are shown in
solid colored lines: green for normal copy number, red for gain and blue
for deletion.

Sensitivity analysis: performance under varying normal cell
contamination studied by in silico spike-in experiments
Genome segmentation and allelic ratio estimation in tumors
is complicated by the fact that tumor samples are often contaminated with normal cells. We define tumor purity to be
the proportion of tumor cells in the sample. To assess the
performance of FALCON under contamination, we created
an in silico spike-in data set (details in the Appendix) where
signals of known length and contamination level are added
to real sequencing data from a normal sample. By spiking
signals into a real sequencing data set, we retain the biases
and other noise properties of real data. The spiked-in signals are categorized by the six possible types shown in Table 3, and the width and locations of the spike-in signals
are shown in Figure 6, which also shows FALCON’S ASCN
estimates when the tumor purity is only 25%.
Except for balanced gain/loss, all other types of allelespecific aberration also involve total copy number change,
and thus conceptually can also be found by methods based
on total copy number. We compared the performance of
FALCON to seqCBS(15), a segmentation method based on
comparing the total coverages between tumor and matched
normal. Both methods use a modified BIC for selecting the
number of change-points. Table 3 shows the smallest tumor
purity under which a given aberration can be detected by
each of the two approaches. For falcon, we also require
that the aberration type of a given call to be correctly identified for it to count as a true positive; whereas for seqCBS,
we only require the called region to overlap the true region. Note that segmenting based on allele-specific coverage
allows us to attain much higher sensitivity than segmenting based on total coverage for all aberration types except
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loss/loss, in which case the two methods have comparable
sensitivity.
The sequencing data we used for the spike-in has ∼44×
coverage. To assess the sensitivity of FALCON under lower
coverage, we downsampled the data (details in the Appendix) and created spike-in data with 22× and 11× coverage. Table 4 shows, under the three levels of coverage, the
smallest tumor purity under which a given aberration can
be detected by falcon and seqCBS (in parentheses). We
see that, as the coverage decreases, the sensitivity also decreases: Under 44× coverage, falcon can detect all types of
aberrations if the purity of the tumor is 1/4; under 22× coverage, it needs purity 2/5 to detect all types of aberrations;
and under 11× coverage, it needs purity around 1/2. Under all three levels of coverage, falcon is significantly more
sensitive than seqCBS except for the change type ‘loss/loss’.
Both methods can detect loss/loss at very low tumor purity
even for low coverage. Under 22× and 11× coverage, the
sensitivity of falcon for loss/loss events is slightly lower
than seqCBS. This is because we require that falcon must
correctly identify the aberration, i.e. to determine that both
parental chromosomes undergo loss, whereas we only require that seqCBS detects the breakpoints.
CONCLUSION
We presented a method, implemented in the software
falcon, for estimating ASCN from next-generation sequencing data of tumors with matched normals. falcon
is based on a bivariate mixed Binomial process for allelespecific coverage in the two samples at heterozygous variant loci. By conditioning on the matched normal sample,
FALCON segments the genome into regions of homogeneous
allele-specific coverage.
We evaluated the accuracy of FALCON in two ways: First,
we applied falcon to the analysis of a trio of normal, premalignant lesion and late-stage colorectal tumor samples
from the same individual, and validated 10 of 13 small
single-copy events called by falcon using ddPCR. As discussed in Results, substantial evidence suggests that 2 of the
3 events that are not validated by ddPCR are true. Second,
with a spike-in data set where events of varying purity are
added to a real sequenced normal sample, we show thatfalconaccurately detects copy number events at low purity. The
allelic ratios given by falconon the trio of samples
from the colorectal cancer patient allow the computation of event-wise purities which led to a detailed analysis of its clonal history including a deduction of the order
of mutations in the progression to late-stage disease.
Falcon requires a paired normal from the same individual, this is because it assumes that the tumor and control
shares the same set of heterozygous SNVs. In centromeres
or telomeres, high mapping error can cause wildly fluctuating coverage as well as a high incidence of false SNV calls.
Thus, we recommend masking these regions prior to analysis by falcon. To first order, falcon is not sensitive to GC
bias due to its use of a normal control. However, it is quite
important that the normal control be processed in the same
way as the tumor sample.
Falcon’s processing time is linear in the number of loci
and does not depend on the sequencing depth. In an hour,
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falcon can process 240 000 loci on a laptop with Intel Core
i5-2410M processor. The colorectal cancer patient has ∼2
million identified heterozygous variant loci, which was processed by falcon in 8 h on a single processor. Falcon is
easy to parallelize by processing each chromosome separately. Parallelization over chromosomes allows falcon to
process a typical whole genome in 1 h.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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APPENDIX
Parameter estimation in mixed-Binomial model
In this section, we describe how parameters in model (1)
are estimated. We begin with the simplest case, where there
is one changed interval (i.e. K = 2). Then, the parameters τ
and pa , pb can be estimated by maximizing the generalized
likelihood ratio statistic,
i j =

sup
piaj , pibj , p0a , p0b

l1 ( piaj , pibj , p0a , p0b ) − sup l0 ( pa , p b ),
pa , pb

where l1 and l0 are log-likelihood functions, (pa , pb ) are overall success rates, ( piaj , pibj ) are success rates inside the interval
(i, j] and ( p0a , p0b ) are success rates outside the interval. There
is no analytic form of the maximum likelihood estimates
for the success rates because it is a mixture model, but we
can use the expectation-maximization algorithm to estimate
them. The following gives the algorithm for estimating the
overall success rates. The observed allelic coverages are collectively denoted by Z = {XtA, XtB , YtA, YtB : t = 1, . . . , T}.
For the success rates inside or outside the interval, we can
adapt the algorithm by only using the reads inside or outside the interval.
Algorithm A1. EM algorithm for Binomial mixture.
(1) Take initial guesses for the parameters p̂a , p̂ b . For example, p̂a = 0.4, p̂ b = 0.6. (The initial values of p̂a and
p̂ b need to be different.)
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(2) Expectation Step, γ̂t = E(It | p̂a , p̂ b , Z), t = 1, . . . , T:
γ̂t =
1+



1

p̂b
p̂a

 XtA−XtB 

1− p̂b
1− p̂a

with

YtA−YtB .
=



τ K+1

t=τk +1

∂ 2l(θK , τK )
∂(θka )2
(XtA−XtB −(n tA−n tB )h  (θka ))2 f1 (t,θk ) f2 (t,θk )
( f1 (t,θk )+ f2 (t,θk ))2

(3) Maximization Step, update p̂a and p̂ b :
p̂a =
p̂ b =

−

T
(XtAγ̂t +XtB (1−γ̂t ))
t=1
,
T
A
B
t=1 (n t γ̂t +n t (1−γ̂t ))
T
(XtA(1−γ̂t )+XtB γ̂t )
t=1
.
T
A
B
t=1 (n t (1−γ̂t )+n t γ̂t )

=

τ K+1

i j = l1 ( p̂iaj , p̂ibj , p̂0a , p̂0b ) − l0 ( p̂a , p̂ b ).
We find (i, j) such that ij is maximized and they are estimates of the boundaries of the changed interval. For multiple change-points, we adapt the Circular Binary Segmentation approach (16,17), which searches for changed intervals
recursively, that is, to search for changed intervals in the resulting segments from the previous search.

=

τ K+1

t=τk +1



,

(XtA−XtB −(n tA−n tB )h  (θka )) f1 (t,θk )
f1 (t,θk )+ f2 (t,θk )

×

Let p̂ be the maximum likelihood estimates, then



∂ 2l(θK , τK )
∂θka ∂θkb

t=τk +1

(4) Iterate steps 2 and 3 until convergence.



h (θka )(n tA f1 (t,θk )+n tB f2 (t,θk ))
f1 (t,θk )+ f2 (t,θk )

(XtB −XtA−(n tB −n tA)h  (θkb )) f2 (t,θk )
,
f1 (t,θk )+ f2 (t,θk )

∂ 2l(θK , τK )
∂(θkb )2
(XtB −XtA−(n tB −n tA)h  (θkb ))2 f1 (t,θk ) f2 (t,θk )
( f1 (t,θk )+ f2 (t,θk ))2

−



h (θkb )(n tB f1 (t,θk )+n tA f2 (t,θk ))
f1 (t,θk )+ f2 (t,θk )



,

and


a
b
f1 (t, θk ) = exp XtAθka − n tA log(1 + eθk ) + XtB θkb − n tB log(1 + eθk ) ,


a
b
f2 (t, θk ) = exp XtB θka − n tB log(1 + eθk ) + XtAθkb − n tA log(1 + eθk ) ,
h(θ)

Determining the number of homogeneous segments
In this section, we determine the number of change-points
through model selection procedure guided by a modified
Bayes information criterion extended from that of (18). We
want to find K such that P(MK |Z) is maximized. We work
under the uniform prior on (K, τK , θK ), where θK is the reparametrized parameters in the Binomial distribution:
θka = log

pka
pkb
b
,
θ
=
log
, θk = (θka , θkb ),
1 − pka k
1 − pkb
θK = (θ0a , θ0b , . . . , θ Ka , θ Kb ).

When T is large, the leading terms for log
l(θ̂K (τ̂K )) − l(θ̂ 0 ) −

1
2

K

i =0

P(MK |Z)
P(M0 |Z)

is

log |Hk (θ̂K (τ̂K ))|

+ 12 log |H(θ̂ 0 )| − K log T
where

τ̂K = (τ̂1 , . . . , τ̂K ) =

(A1)

arg max l(θ̂K (τK )),

0<τ1 <···<τK <T

and

θ̂K (τK ) are maximum likelihood estimates given break
points τK , which can be estimated through Algorithm A1,
and

=

|Hk (θ̂K (τ̂K ))|
 2
2
∂ 2l(θK (τ̂K )) ∂ 2l(θK (τ̂K ))
∂ l(θK (τ̂K ))
−
∂(θka )2
∂(θkb )2
∂θka ∂θkb

,
θk =θ̂k
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= log(1 + eθ ).

We maximize Equation (A1) to decide K, the number of
change-points, for the sequence.
ddPCR for validating focal events
To validate selected single-copy focal losses, we utilized a
ddPCR platform with a single-color DNA binding dye,
EvaGreen. The nature of the EvaGreen dye ensures a difference in fluorescent amplitude with different amplicon
lengths. The methods for the multiplexed, single color, copy
number assay and the manipulation of amplicon length by
the addition of tandem repeats at the 5 -end of a given
primer were described in (19). We designed a multiplexed
assay for each region of interest (ROI) by using the same
diploid gene, FOXI3, as internal reference within each assay and capitalizing on a difference in amplicon length to
distinguish droplets containing template for the ROI, the
reference or both.
The PCR reaction was prepared with 1× EvaGreen Supermix (Bio-Rad), 50 nM each reference and ROI primers, 20
ng of DNA template pre-digested with EcoRI (NEB) and
water to a final reaction volume of 20 l. We generated
droplets and thermally sealed the 96-well plates according
manufacturer’s recommendations. PCR was cycled at the
following conditions: 95◦ C for 10 min; 40 cycles of 95◦ C for
30 s and 60◦ C for 60 s; 98◦ C for 10 min and held at 4◦ C until processing. After PCR, the plate was read on the QX200
droplet reader (Bio-Rad). The fluorescent droplet data was
exported and analyzed by a custom clustering MatLab program based on Ward’s Method as the objective function.
We ran each sample in triplicate and calculated a weighted
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average and standard deviation for each copy analysis. We
verified primer targets via Sanger sequencing.
Detailed plots
Here, we provide detailed plots for events listed in Table
1. The event is plotted in the middle bounded by two red
solid verticle lines. Each plot contains three panels: The top
panel shows A-allele frequency in tumor (black) and normal (gray) samples (the horizontal blue line is at 0.5 level);
the middle panel shows relative total coverage of the tumor
sample versus the normal sample (the horizontal blue line
is at 1.0 level); the bottom panel shows the estimated allelespecific copy number from falcon (in bold and dashed horizontal lines) and the observed allele-specific copy number
computed by (6) for the A allele (blue) and the B allele
(pink). For the pre-malignant sample, the first four events
are plotted.
Event-specific purity analysis
Assuming a genome-wide ploidy of 1 (this is supported by
our data, which we will explain later), the relationships between event-specific purity f and the minor and major allelic ratios output by falcon are simple for three of the six
types of events: For normal/loss regions, the minor allelic
ratio is [(1 − f) × 1 + f × 0]/1 = 1 − f. For gain/normal
regions, let c > 1 be the copy number of the amplified allele in cells containing this event, then the major allelic ratio is [(1 − f) × 1 + f × c]/1 = 1 + f(c − 1). For balanced
gain/loss regions, the minor allelic ratio is 1 − f and the
major allelic ratio is 1 + f. For gain/gain and loss/loss regions, the relationships between f and the allelic ratios are
more complicated since these regions are likely due to two
or more mutation events which may not always be carried
by the same cells. Therefore, the relationship between f and
the major and minor allelic ratios does not depend on any
unknowns for normal/loss and balanced gain/loss regions
(for gain/normal regions, the relationship depends on the
unknown c). Thus, without further assumptions, we can directly compute an estimate of f for normal/loss and balanced gain/loss regions from the estimated major and minor allelic ratios given by falcon.
We have conducted the reasoning assuming a genome-wide
ploidy of 1, which we believe is true for our data due to the
tightness of the clusters in Figure 4. Our reasoning is as follows: Let γ ∈ {1, 2, . . . } be the unknown ploidy of a tumor
sample; that is, by default, the allele-specific copy numbers
at each variant site is γ . Then, the copy number of a minor
allele after loss is no longer 0, but takes value cγ , where c
∈ {0, 1/γ , 2/γ , . . . , (γ − 1)/γ }. For example, if baseline
ploidy is 3, the copy number after a loss can be 0, 1 or 2.
Then, the minor allele ratio is 1 − f(1 − c). Note that γ does
not appear in this equation, but it implicitly determines the
range of values for c. Thus, when ploidy is unknown, f is
no longer identifiable even for normal/loss and balanced
gain/loss events. The tightness of the clusters suggest that,
barring the unlikely scenario that changes in f cancel out the
changes in c, all mutations within the same cluster should
have the same cellular fraction and absolute copy number,
and thus even if ploidy is not 1, the qualitative conclusions
made in the preceding paragraphs hold.
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Deducing the clonal history
The tightly clustered event-wise purities in Figure 4 allows
us to conclude the following facts: (i) Due to the existence of
high confidence events (groups A and D) that are shared between the two samples, we can be quite certain that the advanced stage tumor evolved from precursor cells in the premalignant tumor. (ii) The mutations in group C are present
in the pre-malignant sample but not in the sample from the
advanced stage tumor, whereas those in group D are present
in both samples. This implies that in the pre-malignant sample, there are cells which contain mutation group D but not
mutation group C, and that those cells which carry mutation
group C were not genetic precursors of the late-stage malignant tumor. (iii) The mutations in group E are present in the
advance stage sample but not in the pre-malignant sample.
Thus, although the mutations in group E have the same purity as group D in the advance stage tumor, we know with
certainty that the group E mutations were acquired at a later
time than those in group D. (iv) Finally, the group A mutation have approximately the same purity level in the advanced stage tumor as the mutations in groups E and D,
but significantly lower purity in the pre-malignant sample
than the group D mutations. There is only one logical explanation for this: The subpopulation that carried mutation group D acquired mutation A before the pre-malignant
sample was taken, and then went on to acquire mutation
group E en route to malignancy. Together, these facts imply
that one of the two histories presented in Figure 5 must be
true for this tumor.
Generating the spike-in data
To make the spike-in data, we started with all reads mapping to a section of Chromosome 7 from the normal sample. We then added the six different aberration types in positions and magnitudes shown in Table A1. To generate the
sequence of reads, we first randomly generated a genotype,
It , for each location t with both AB and BA being equally
likely and It = 1 if the genotype is AB. The true reads in the
real data on alleles A and B at location t serve as the intensities, A (t) and B (t), for the control reads, YtA and YtB :
YtA ∼ Poisson(λ A(t)),

YtB ∼ Poisson(λ B (t)).

The intensities for the case reads are determined by the signals in that region. For instance, if the true copy number in
the region is (c1 , c2 ), then,
μ A(t) = (c1 It + c2 (1 − It ))λ A(t),
μ B (t) = (c1 (1 − It ) + c2 It )λ A(t),
and the case reads, XtA and XtB , are sampled randomly:
XtA ∼ Poisson(μ A(t)),

XtB ∼ Poisson(μ B (t)).

Figure A1 plots the relative coverage ((XtA + XtB )/(YtA +
YtB )) and the observed allele-specific copy number calculated by Equation (4) for the simulated data under 100%
tumor purity and 25% tumor purity.
For downsampling (Table 4), A (t) and B (t) are divided by
2 to get 20× coverage, and divided by 4 to get 10× coverage.
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Table A1. Signals imposed on to a segment of Chromosome 7
Type of change
Gain/Normal
Gain/Gain
Normal/Loss
Loss/Loss
Balanced Gain/Loss
Unbalanced Gain/Loss

SNV begin

SNV end

Copy number

301
801
1301
1801
2301
2801

500
1000
1500
2000
2500
3000

(2,1)
(2,2)
(1,0)
(0,0)
(2,0)
(3,0)

Figure A1. The relative coverage (left panel) and observed allele-specific
copy number (right panel) of simulation data with 100% tumor purity (first
row) and 25% tumor purity (second row).
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